Newsroom
Sorted by: Latest
-
Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2026 results and recent business performance update. “Ironwood delivered a third consecutive strong quarter as we continue focused execution of our three strategic priorities: maximize LINZESS, advance apraglutide and deliver sustained profits and cas...
-
Versigent CFO to Participate in RBC Capital Markets Global Industrials Conference on November 17
SCHAFFHAUSEN, Switzerland--(BUSINESS WIRE)--Versigent PLC (NYSE: VGNT), a global leader in the design and manufacture of low- and high-voltage electrical architectures, today announced Chief Financial Officer, Doug Ostermann, will participate in a fireside chat at the RBC Capital Markets Global Industrials Conference on Tuesday, November 17, 2026 at 10:40 a.m. ET. The live webcast will be available at the following link: https://kvgo.com/2026-global-Industrials-conference/versigent-plc-november...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 04.11.2026 UNCU.LN IE00BD6GCF16 1,069,907.00 USD 56,611,837.43 52.913 ...
-
Vistance Networks Announces CEO Succession Plan
RICHARDSON, Texas--(BUSINESS WIRE)--Vistance Networks, Inc. (NASDAQ: VISN) today announced Chuck Treadway will step down as President and CEO of the Company on February 1, 2027....
-
Peptilogics Enrolls First International Patient in Phase 2/3 RETAIN Trial of Zaloganan for Treatment of Prosthetic Joint Infection
PITTSBURGH & LEEDS, United Kingdom--(BUSINESS WIRE)--Peptilogics, a clinical stage biotech company dedicated to curing and preventing medical device-related infections (MDRI), today announced that the first patient has been enrolled in the U.K. at Leeds Teaching Hospitals NHS Trust and NIHR Clinical Research Facility: Leeds, in the pivotal RETAIN Phase 2/3 trial of zaloganan (PLG0206) for treatment of prosthetic joint infection (PJI). Led by Investigators Dr. Hemant Pandit, Professor of Orthopa...
-
Aurora Cannabis Announces Fiscal 2027 Second Quarter Results
EDMONTON, Alberta--(BUSINESS WIRE)--Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ | TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2027 ending September 30, 2026. Aurora has cancelled its investor call, originally scheduled for November 12, 2026, at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time, due to the Company’s announcement on November 3, 2026, that Aurora has entered into a defin...
-
Dunham Wins Asset Management STAR Award and Earns Four Luminaries Finalist Honors
SAN DIEGO--(BUSINESS WIRE)--Dunham & Associates Investment Counsel, Inc. (“Dunham”), a San Diego-based asset management firm with more than 40 years of asset management experience, has been named Boutique Winner in the Marketing Innovation category of the Asset Management STAR Awards North America 2026. The award program was developed by the Investment Management Education Alliance (IMEA) in partnership with FT Live, Ignites and FundFire. Winners were recognized October 19, 2026, at the ina...
-
Acacia Research Corporation Reports Third Quarter 2026 Financial Results
NEW YORK--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq: ACTG) (“Acacia” or the “Company”), which acquires and operates businesses across the industrial, energy and technology sectors, today reported financial results for the three and nine months ended September 30, 2026. The Company also posted its third quarter 2026 earnings presentation on its website at www.acaciaresearch.com under Quarterly Results. Martin (“MJ”) D. McNulty, Jr., Chief Executive Officer, stated, “In the third quart...
-
The Middleby Corporation Reports Third Quarter Results
ELGIN, Ill.--(BUSINESS WIRE)--The Middleby Corporation (NASDAQ: MIDD), a global leader in commercial foodservice solutions, today reported net earnings for the third quarter of 2026. Tim FitzGerald, CEO of the Middleby Corporation said, “We delivered record third quarter net sales and strong organic growth across our commercial foodservice business. Adjusted EBITDA increased 10% from the prior year, and our performance exceeded the high end of our guidance ranges for net sales, Adjusted EBITDA...
-
BKV Reports Q3 2026 Results, Cost Reimbursement Agreement with Leading Frontier AI Lab, and Verra Carbon Credit Certification
DENVER--(BUSINESS WIRE)--BKV Corporation (“BKV” or the “Company”) (NYSE: BKV) today reported financial and operational results for the third quarter of 2026, along with guidance for the fourth quarter of 2026. In addition, the Company is announcing an expanded scope for its Phase 1 modular power development in Temple, TX, supported by a Cost Reimbursement Agreement with a Leading Frontier AI Lab, and Verra carbon credit certification. Third Quarter 2026 Highlights Net income attributable to BKV...